| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
5 companies
Michael W Bonney is Director at DNTH, with reported holdings spanning 5 companies. Michael W Bonney's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $21.6M at current prices.
Our model assigns Michael W Bonney a below-average insider score of 42/100, based on 4 past trades. Over a 12-month horizon, 25.0% of those trades were profitable, with an average 12-month return of -4.4%.
Michael W Bonney's largest disclosed position is in DNTH as Director, worth about $17.8M.
Michael W Bonney has 46 Form 4 filings on record from May 2015 to June 2026, across 8 companies: Director at Immunic (IMUX), 2026; Director at Autolus Therapeutics (AUTL), 2026; Director at Alnylam Pharmaceuticals (ALNY), 2015–2025, and 5 more.
The 75 reported transactions were 33 option or other derivative awards, 23 open-market sales, 9 option exercises and 5 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 5 purchases worth about $720K and 4 sales worth about $15.2M.
The largest open-market purchase was 2,000 shares of ALNY at an average $112.16 on May 12, 2015, about $224K.
The largest open-market sale was 30,000 shares of ALNY at an average $195.00 on December 27, 2023, about $5.8M. Twelve months later ALNY was up 23%.
3 of the 4 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other was not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2025 | ALNY Alnylam Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 11,250 | $450.00 | $5,062,500.00 | -40.1% | +0.8% | -50.0% | |
| May 15, 2025 | ALNY Alnylam Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 11,250 | $277.71 | $3,124,216.94 | -40.1% | +52.6% | +1.3% | |
| Dec 27, 2023 | ALNY Alnylam Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 30,000 | $195.00 | $5,850,000.00 | -65.2% | -22.7% | +23.4% | |
| Aug 3, 2023 | ALNY Alnylam Pharmaceuticals, Inc. | Director | Sale+OE | 6,448 | $185.38 | $1,195,310.07 | -28.7% | -17.4% | +43.1% | |
| Dec 4, 2019 | BMY Bristol Myers Squibb Co | Director | Buy | 88 | $58.90 | $5,183.20 | +1.2% | - | - | |
| Sep 9, 2019 | SRPT Sarepta Therapeutics, Inc. | Director | Buy | 2,000 | $86.74 | $173,480.00 | +39.6% | - | - | |
| Mar 9, 2016 | ALNY Alnylam Pharmaceuticals, Inc. | Director | Buy | 2,000 | $58.36 | $116,720.00 | +100.0% | - | - | |
| Aug 17, 2015 | THW Abrdn World Healthcare Fund | Director | Buy | 10,917 | $18.35 | $200,294.20 | New | - | - | |
| May 12, 2015 | ALNY Alnylam Pharmaceuticals, Inc. | Director | Buy | 2,000 | $112.16 | $224,320.00 | New | - | - |